Skip to main content

Table 1 The comparison of baseline characteristics of the participants

From: Randomized double blind clinical trial evaluating the Ellagic acid effects on insulin resistance, oxidative stress and sex hormones levels in women with polycystic ovarian syndrome

Variable Mean ± SD
Placebo(n = 28)
Mean ± SD
Ellagic acid (n = 29)
P1
Age (years, Mean ± SD) 26.09 ± 1.53 25.74 ± 1.19 0.736 Age (years, Mean ± SD)
Height(cm) 160.71 ± 9.28 162.09 ± 8.33 0.77 Height(cm)
Weight (kg) Before 69.71 ± 5.11 70.63 ± 4.15 0.68
After 69.2 ± 5.07 70.06 ± 4.51 0.59
P2 0.651 0.703  
Body Mass Index (K g/m2, Mean ± SD) Before 26.99 ± 0.61 26.88 ± 0.59 0.519
After 26.79 ± 0.62 26.66 ± 0.64 0.53
P2 0.864 0.817  
Physical activity (met-h/week) Before 36.01 ± 3.5 37 ± 3.29 0.218
After 36.11 ± 3.57 37.61 ± 3.41 0.109
P2 0.401 0.347  
Metformin dose 1599.03 ± 404.26 1609.11 ± 395.13 0.721
  1. Data are expressed as means ± SD
  2. P1: Comparison of the mean of baseline characteristics between the two groups of Ellagic acid and placebo (Independent samples t-test)
  3. P2: Comparison of mean of baseline characteristics in each group at baseline and end of study (Paired samples t-test)